Overview and Mission

Under the directorship of Dr. Alexei Bogdanov, the mission of the LMIP is to develop diagnostic and theranostic contrast agents and sensing probes capable of detecting/ treating human disease at its earliest stage. Our most recent efforts have been focused on applying both well-established and emerging cross-sectional in vivo imaging modalities (magnetic resonance imaging, photoacoustic, fluorescence lifetime tomographies) to detect and measure real-time, molecular-level physiological events so as to gain a better understanding of disease development and progression in realistic animal models of human disease. We believe that these imaging probes and sensors, along with the technical advances that result from their application in vitro and in vivo, will be of future use in high-content screening and will ultimately be translatable to diagnostic imaging strategies in vivo.